within Pharmacolibrary.Drugs.N_NervousSystem.N04A_AnticholinergicAgents.N04AA03_Metixene;

model Metixene
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.3,
    Cl = 4.9999999999999996e-06,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.005,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Metixene</td></tr><tr><td>ATC code:</td><td>N04AA03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>300</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Metixene is an anticholinergic drug used primarily in the treatment of Parkinson's disease and drug-induced extrapyramidal symptoms. It acts as a muscarinic receptor antagonist, reducing tremor and rigidity. Metixene is no longer widely used and is not approved in many countries today.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed publications reporting pharmacokinetic models or parameters for metixene in humans were identified. The following are estimated parameters based on the general properties of anticholinergic drugs in the same therapeutic class.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N04AA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Metixene;
